[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648389":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":37,"responsibleParty":52,"collaborators":11,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":11,"enrollmentInfo":65,"targetDuration":11,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":39,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Seoul National University Bundang Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cilostazol","EXPERIMENTAL",null,[13],"Drug: Cilostazol",{"label":15,"type":16,"description":11,"interventionNames":17},"Aspirin","ACTIVE_COMPARATOR",[18],"Drug: Aspirin",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Drug: Cilostazol Other Name: Pletaal SR Capsule",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"Drug: AspirinOther Name: ASA",[15],[28,33],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Soo Lim","CONTACT","82-10-9766-2706","limsoo@snu.ac.kr",{"name":34,"role":30,"phone":35,"phoneExt":11,"email":36},"Jiyoon Lee","82-10-4850-4828","rq857@snubh.org",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":11,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Seongnam-si","Gyeonggi-do","13620","South Korea",{"type":45,"coordinates":46},"Point",[47,48],127.13778,37.43861,{"lat":48,"lon":47},[51],{"name":34,"role":30,"phone":35,"phoneExt":11,"email":11},{"type":53,"investigatorFullName":29,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Professor","100648389","phase-4-cilostazol-and-aspirin-for-cardiovascular-event-prevention-in-patients-with-type-2-diabetes-100648389",false,"NCT07719894","Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes","Comparison of Efficacy and Safety Between Aspirin and Cilostazol on Cardiovascular Event in Patients at High Risk of Cardiovascular Disease, Randomization.","Cilo-Asa","Inclusion Criteria:\n\n* Individuals with type 2 diabetes mellitus were eligible if they were aged ≥19 years\n* Individuals with subclinical atherosclerosis or metabolic syndrome, defined as at least one of the following:\n* Carotid intima-media thickness ≥ 1 mm\n* Ankle-brachial index \\\u003C 0.9 - Pulse wave velocity ≥ 9 m\u002Fs\n* Flow-mediated vasodilatation \\\u003C 5%\n* Coronary artery calcium score ≥ 40\n* Coronary artery stenosis ≥ 20% or ≤ 70%\n* Peripheral artery occlusive disease ≥ 20%\n* Metabolic syndrome\n* Individuals with HbA1c ≤ 9.9%\n* Individuals who voluntarily agree to participate in the study and provide written informed consent\n\nExclusion Criteria:\n\n* Patients with a history of major cardiovascular events, including myocardial infarction, stroke, or heart failure\n* Patients with heart failure (NYHA I\\~IV)\n* Patients with current active bleeding or suspected bleeding\n* Patients with suspected bleeding tendency or hematologic disorder, such as hemophilia or thrombocytopenia\n* Patients recently diagnosed with gastrointestinal ulcerative disease\n* Patients with inadequately controlled hypertension, defined as systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg\n* Patients with severe renal dysfunction, defined as estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m²\n* Patients with liver enzyme levels greater than 3 times the upper limit of normal or chronic liver disease\n* Individuals currently taking antiplatelet or antithrombotic agents\n* Individuals who are pregnant or breastfeeding\n* Patients with a history of hypersensitivity to any component of the study drugs\n* Patients with complications of coronary artery stenosis\n* Patients with QT prolongation\n* Patients with a sigmoid-shaped ventricular septum or risk of sigmoid-shaped ventricular septum\n* Individuals with alcohol addiction\n* Patients with asthma\n* Patients deemed unsuitable for participation in the study based on the investigator's judgment","ALL","19 Years",{"count":66,"type":67},1200,"ESTIMATED","INTERVENTIONAL",[70],"PHASE4","Patients with type 2 diabetes and cardiovascular risk factors are at increased risk of cardiovascular events. Therefore, a multi-center prospective randomized study will be conducted to compare the efficacy and safety of cilostazol and aspirin for the prevention of major adverse cardiac and cerebrovascular events (MACCE) in high-risk patients with type 2 diabetes.",[73,74],"Type 2 Diabetes Mellitus (T2DM)","Atherosclerosis",[76,9,15],"Major Adverse Cardiac and Cerebrovascular Events","2026-07-19",{"date":79,"type":80},"2026-07-22","ACTUAL",{"date":82,"type":80},"2026-05-06",{"date":84,"type":67},"2028-12-31",{"name":5,"class":6},1]